Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.63 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.51 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27788276 | 0.90 | EGFR (0.66) | EGFRCSNK1DMAP4K4ERBB2MAPK9 | |
| SCHEMBL3668786 | 0.84 | EGFR (0.57) | EGFRCSNK1DMAP4K4ERBB2MAPK9 | |
| SCHEMBL3670036 | 0.82 | MAPK14 (0.64) | EGFRCSNK1DMAP4K4ERBB2MAPK9 | |
| SCHEMBL4294191 | 0.80 | EGFR (0.90) | EGFRCSNK1DMAP4K4ERBB2MAPK9 | |
| SCHEMBL4292705 | 0.77 | EGFR (1.00) | EGFRCSNK1DMAP4K4ERBB2MAPK9 | |
| Isopropylamine SCHEMBL4791212 | 0.71 | MAPK14 (0.47) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL6004451 | 0.71 | CSNK1D (0.48) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL18041924 | 0.71 | EGFR (0.69) | EGFRCSNK1DMAP4K4ERBB2MAPK9 | |
| SCHEMBL6004454 | 0.70 | CSNK1E (0.47) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL3668088 | 0.70 | EGFR (0.78) | EGFRCSNK1DMAP4K4ERBB2MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101790526-A | 5-heteroaryl substituted indazoles as kinase inhibitors | ABBOTT GMBH & CO KG | 2010-07-28 | — | — | CN | claimed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | claimed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| CN-101790526-A | 5-heteroaryl substituted indazoles as kinase inhibitors | ABBOTT GMBH & CO KG | 2010-07-28 | — | — | CN | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | EGFR 876/4885CSNK1D 143/4885MAP4K4 51/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | EGFR 876/4885CSNK1D 143/4885MAP4K4 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.